Texas Instruments (TI) (NASDAQ: TXN) today announced the new SimpleLink™ ultra-low power wireless microcontroller (MCU) platform that helps customers go battery-less with energy harvesting or enjoy always-on, coin cell-powered operation for multiple years. With this industry-first technology, customers have the flexibility to develop products that support multiple wireless connectivity standards using a single-chip and identical RF design. The SimpleLink ultra-low power platform supports Bluetooth® low energy, ZigBee®, 6LoWPAN, Sub-1 GHz, ZigBee RF4CE™ and proprietary modes up to 5Mbps. This platform expands TI’s SimpleLink portfolio, the broadest, lowest power and easiest to use wireless connectivity offering in the industry for the Internet of Things (IoT). For more information, visit www.ti.com/simplelinkulp.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/70647527-texas-instruments-simplelink/
Expanding the functionality of Internet of Things (IoT) networks, Texas Instruments (TI) (NASDAQ: TXN) today announced availability for mass production of the industry’s lowest-power dual-band wireless microcontroller (MCU) supporting Sub-1 GHz and Bluetooth® low energy connectivity on a single chip. As part of TI’s pin-to-pin and software compatible SimpleLink™ ultra-low power platform, the new SimpleLink dual-band CC1350 wireless MCU enables developers to move from a three-chip solution to a tiny single chip, while reducing design complexity, saving power, cost and board space. The CC1350 wireless MCU offers a range of up to 20 km on a coin cell battery for building and factory automation, alarm and security, smart grid, asset tracking and wireless sensor network applications. For more information, visit www.ti.com/cc1350-pr.
To view the multimedia release go to:
http://www.multivu.com/players/English/7746254-texas-instruments-simplelink-dual-band-cc1350/
Today, Novo Nordisk announced a four-year extension of its Changing Diabetes® in Children programme which provides access to diabetes care and free insulin to children with type 1 diabetes in developing countries. The expansion sees five new countries join the programme; Cambodia, Ivory Coast, Myanmar, Senegal and Sudan. By 2020, more than 20,000 children over the course of 11 years will have benefited from the programme.
Ten years ago, a child in Sub-Saharan Africa diagnosed with type 1 diabetes often had a life expectancy of less than a year1. In response, Novo Nordisk established the Changing Diabetes® in Children programme to support sustainable quality care and improved diagnosis of the condition. Since the start of the programme in 2009, 13,700 children in nine countries in Africa and South-East Asia have received free human insulin and access to diabetes care.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7962351-novo-nordisk-programme-children-diabetes/
